Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.55 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 8/20 | 0.54 |
| ▸ | MAOA | P21397 | 5/20 | 0.54 |
| ▸ | GRM5 | P41594 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8545870 | 0.86 | RAB9A (0.71) | RAB9AMAOBMAOA | |
| SCHEMBL8785132 | 0.81 | MAOB (0.62) | RAB9ASPHK2SPHK1MAOBMAOA | |
| SCHEMBL4060195 | 0.81 | MAOB (0.62) | RAB9ASPHK2SPHK1MAOBMAOA | |
| SCHEMBL12640896 | 0.81 | FFAR1 (0.53) | FFAR1RAB9AMAOBMAOA | |
| SCHEMBL1248693 | 0.81 | MAOB (0.66) | FFAR1FFAR4MAOBMAOAGRM5 | |
| SCHEMBL9034724 | 0.80 | ALDH1A1 (0.61) | RAB9AMRGPRX4 | |
| SCHEMBL27983208 | 0.80 | RAB9A (0.63) | RAB9AMAOBMAOA | |
| SCHEMBL8549374 | 0.80 | FFAR1 (0.60) | FFAR1FFAR4RAB9AMAOBMAOA | |
| SCHEMBL2015368 | 0.80 | FFAR1 (0.60) | FFAR1FFAR4MAOBMAOAGRM5 | |
| SCHEMBL22874523 | 0.80 | MAOB (0.62) | FFAR1FFAR4RAB9AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107151220-B | Phenol compound containing benzyloxy phenyl, preparation method and application thereof | 中国医学科学院药物研究所 | 2021-07-20 | — | — | CN | disclosed |
| EP-1727788-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1727788-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7381750-B2 | Amino-phenoxymethyl-benzamide opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381750-B2 | Amino-phenoxymethyl-benzamide opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-RE40259-E1 | side effects reduction; compounds active on the central nervous system; chronic and neuropathic pain, anti-epileptic, anti-Parkinson, neuroprotective, antidepressant, antispastic and hypnotic agents; 2-[4-(3-fluorobenzyloxy)benzylamino]-2-methylpropanamide | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2008-04-22 | — | — | US | disclosed |
| US-20070287751-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070287751-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY | 2007-12-13 | — | — | US | disclosed |
| EP-1727788-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005090286-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005000309-A2 | CHEMICAL COMPOUNDS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-06 | — | — | WO | disclosed |
| EP-1045830-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARM SPA (IT) | 2003-04-23 | — | — | EP | disclosed |
| US-6306903-B1 | ANALGESICS FOR ALLEVIATION OF CHRONIC AND NEUROPATHIC PAIN. | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2001-10-23 | — | — | US | disclosed |
| EP-1045830-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035125-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287751-A1 | Opioid Receptor Antagonists | OPRK1, OPRM1, OPRD1 | FFAR1 56/4885FFAR4 167/4885RAB9A 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.